Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 8Cisplatin 8pembrolizumab 5durvalumab 4Specimen Handling 3Platinum 3Oxaliplatin 3Leucovorin 31,2-diaminocyclohexaneplatinum II citrate 3Taxes 2Nivolumab 2Magnetic Resonance Spectroscopy 2Folfox protocol 2Fluorouracil 2Biopsy 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2zanidatamab 1trastuzumab deruxtecan 1peposertib 1guadecitabine 1fludarabine 1dehydroftorafur 1binimetinib 1avelumab 1Trastuzumab 1Radiation Dose Hypofractionation 1Radiation 1Paclitaxel 1Lymph Node Excision 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gallbladder Neoplasms × guadecitabine × 90 days × Clear all
NCT03257761 2026-06-01

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

University of Southern California

Phase 1 Active not recruiting
55 enrolled
Gastrointestinal

Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡